Scholarlink

Purpose <p>Invasive fungal disease (IFD) represents a&#xa0;major cause of morbidity and mortality in pediatric patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy treatment. While primary antifungal prophylaxis is known to reduce the incidence of IFD, data on pediatric AML patients are sparse. This study assessed the usage and outcomes of antifungal prophylaxis in this high-risk group, contributing to the limited data available on pediatric AML.</p> Material and methods <p>We conducted a&#xa0;retrospective analysis of 394 cycles of antifungal prophylaxis in 92&#xa0;pediatric patients with de novo AML at our center. Prophylaxis included amphotericin&#xa0;B derivatives (<i>n</i> = 139), itraconazole (<i>n</i> = 107), or voriconazole (<i>n</i> = 148), reflecting varied clinical choices over the study period.</p> Results <p>At least one adverse event was observed in 93% of cycles with antifungal prophylaxis. Most patients experienced only low-grade toxicity, and there was no life-threatening adverse event. Creatinine increase, potassium loss, and episodes with vomiting were significantly more frequent with amphotericin&#xa0;B prophylaxis. Discontinuation of antifungal prophylaxis due to an adverse event was necessary in 3% of cycles. The observed incidence of IFD was 7% across the patient cohort, with no significant difference between drugs. No IFD-related death was reported.</p> Conclusion <p>Our analysis highlights a&#xa0;reasonable balance between tolerability and efficacy of antifungal prophylaxis in pediatric AML patients. While the incidence of IFD aligns with previous reports, our cohort demonstrated notably lower mortality. This retrospective audit supports the continued use of voriconazole for its lower associated toxicity, providing a&#xa0;valuable reference for antifungal management in pediatric AML settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating antifungal prophylaxis strategies in pediatric acute myeloid leukemia: a retrospective, single-center analysis of amphotericin B, itraconazole, and voriconazole

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月15日

查看全文
  • Anna Cvrtak,
  • Heidrun Boztug,
  • Nora Mühlegger,
  • Andishe Attarbaschi,
  • Gernot Engstler,
  • Waltraud Friesenbichler,
  • Michael N. Dworzak

摘要

Purpose

Invasive fungal disease (IFD) represents a major cause of morbidity and mortality in pediatric patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy treatment. While primary antifungal prophylaxis is known to reduce the incidence of IFD, data on pediatric AML patients are sparse. This study assessed the usage and outcomes of antifungal prophylaxis in this high-risk group, contributing to the limited data available on pediatric AML.

Material and methods

We conducted a retrospective analysis of 394 cycles of antifungal prophylaxis in 92 pediatric patients with de novo AML at our center. Prophylaxis included amphotericin B derivatives (n = 139), itraconazole (n = 107), or voriconazole (n = 148), reflecting varied clinical choices over the study period.

Results

At least one adverse event was observed in 93% of cycles with antifungal prophylaxis. Most patients experienced only low-grade toxicity, and there was no life-threatening adverse event. Creatinine increase, potassium loss, and episodes with vomiting were significantly more frequent with amphotericin B prophylaxis. Discontinuation of antifungal prophylaxis due to an adverse event was necessary in 3% of cycles. The observed incidence of IFD was 7% across the patient cohort, with no significant difference between drugs. No IFD-related death was reported.

Conclusion

Our analysis highlights a reasonable balance between tolerability and efficacy of antifungal prophylaxis in pediatric AML patients. While the incidence of IFD aligns with previous reports, our cohort demonstrated notably lower mortality. This retrospective audit supports the continued use of voriconazole for its lower associated toxicity, providing a valuable reference for antifungal management in pediatric AML settings.